Context Therapeutics to Present Poster at SITC 39th Annual Meeting

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical enterprise focused on advancing T cell engagers for the treatment of solid tumors, has announced that a poster presentation detailing its clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody, will be showcased at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. This event is scheduled to take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.

The presentation, titled "Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6," will be delivered by authors Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz. This will occur on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB.

CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6, or Claudin 6, is highly present in various solid tumors such as ovarian, endometrial, lung, gastric, and testicular cancers. Preclinical studies have indicated that CTIM-76 could offer convenient dosing options with a low risk of immunogenicity and scalable manufacturing processes. This makes it a promising candidate for treating a substantial number of patients who may benefit from such a therapy.

Context Therapeutics Inc., headquartered in Philadelphia and listed on Nasdaq under the ticker symbol CNTX, is dedicated to developing T cell engaging bispecific antibodies aimed at solid tumors. The company’s innovative portfolio includes CTIM-76, a Claudin 6 x CD3 bispecific antibody; CT-95, a Mesothelin x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody. Through these advanced therapeutic options, Context aims to address various solid tumor challenges and improve patient outcomes.

For more details on the presentation and to view the abstract, individuals can visit the SITC 39th Annual Meeting website.

For additional information about Context Therapeutics and its work in advancing T cell engaging bispecific antibodies, interested parties are encouraged to visit the company's website or follow their updates on social media platforms like X (formerly Twitter) and LinkedIn.